Virtual Library

Start Your Search

Seyda Demirkol



Author of

  • +

    P2.03 - Biology (ID 162)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Biology
    • Presentations: 2
    • Now Available
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.03-51 - Gene Variants and Expressions of Galectin-3 Is Associated with Non Small Cell Lung Cancer and Vascular Invasion of the Tumor (Now Available) (ID 2574)

      10:15 - 18:15  |  Author(s): Seyda Demirkol

      • Abstract
      • Slides

      Background

      Galectin-3 is a β-galactoside binding protein and known for its deregulation in cancer. In previous studies, correlations between single nucleotide polymorphisms (SNP) and cancer development have been identified in the context of genetic susceptibility to different types of cancer. However, potential phenotypic variations related to galectin-3 SNPs have not yet been evaluated in non-small cell lung cancer (NSCLC).

      Method

      In this study, it was aimed to correlate expression levels of gene and protein galectin-3 with genotype and allele distribution of rs4644 and rs4652 SNPs of galectin-3 between NSCLC patients (n=65) and healthy control (n=95) individuals. SNPsrs4644 and rs4652 in galectin-3 were studied using TaqMan Real-Time PCR system. Tissue gene expression levels of galectin-3 for patients was also analysed by Real-Time PCR. Galektin-3 serum levels were measured by ELISA.

      Result

      There were no significant differences in genotype and allele distribution of SNPs and galectin-3 gene expression levels between the tumor tissues compared to tumor surrounding tissues (p> 0.05); Mean serum level of galectin-3 was significantly higher in patients (26.05 ± 1.77 ng / ml) than that of controls (11.62 ± 1.30 ng/ml) (p <0.0001). The presence of angiolymphatic invasion was statistically significantly associated with AA genotype (p = 0.04). SNP rs4644 AC/CC genotype was found to be associated with higher serum galectin-3 levels in patients compared to that of controls (p<0.0001) while SNP rs4652 with AA / AC genotype was associated with lower serum galectin-3 levels in controls compared to patients (p<0.0001). Serum galectin-3 level has been shown to be statistically significantly associated with of vascular invasion among patients who had AC genotypes for both SNPs rs4644 and rs4652 (p = 0.03; p = 0.019 respectively).

      Conclusion

      Galectin-3 could be defined as a possible biomarker for NSCLC and it plays a role as surrogate marker for vascular invasion in tumors.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

    • +

      P2.03-56 - Polymorphism ICAM-1 and Beta-3 Integrin Are Associated with the Development of Non-Small Cell Lung Cancer and the Prognostic Role of ICAM-1 (Now Available) (ID 2615)

      10:15 - 18:15  |  Author(s): Seyda Demirkol

      • Abstract
      • Slides

      Background

      Lung cancer is widespread cancer in the worldwide. Non-small cell lung cancer (NSCLC) accounts for 80-85% of all lung cancers. ICAM-1 and β3 integrin have been have been found to be associated with the angiogenesis, tumor growth and metastasis in various tumor types. Our primary aim in this study was to explore gene polymorphisms in ICAM-1 and β3 integrin molecular pathway in NSCLC patients and to clarify whether these values are effective on the etiopathogenesis and prognosis of the disease.

      Method

      Sixty-nine patients with operable (T1-4N0-1M0) NSCLC patients and 120 healthy individuals between January 2012 and June 2018 were included in the study. The tumor samples were taken after resected specimen. Blood samples of the patients were also collected before surgical resection. ICAM-1 and β3 integrin gene polymorphisms were determined by using PCR-RFLP techniques. Also serum ICAM levels were determined by ELISA method. The stages of the tumor were constructed according to 8th staging system.

      Result

      There was no statistically significant difference between patient with NSCLC and healthy control groups with regard to β3 Integrin Leu33Pro gene polymorphism(p=0.182). However, in patients with NSCLC, AG genotype frequency and G allele carriers of ICAM K469E variant were found to be higher than the control group and the difference was statistically significant(OR:2,710 95%CI:1,364-5,376; p=0.005). It has been determined that having a G allele increased approximately 2,95 fold the risk of disease and also carrying of AGTC combined genotype increased(OR:2,95 95%CI:1,366-6,373;p=0.049). When patients were evaluated according to tumor stage, serum levels of ICAM-1 gene in early tumor stage was found to be significantly higher than in advanced tumor stage (p=0,013). No significant difference was found between the range of histopathological subtypes and serum ICAM levels (p>0,05). Also, no statistically significant association was found between serum ICAM levels and angiolymphatic invasion (p=0.101, perineural invasion(p=0.054), lymph node metastasis (p=0.585).

      Conclusion

      ICAM-1 as an intercellular adhesion molecule seems to play an important role in lung carcinogenesis and it might play a role in the invasiveness of the tumor. However, β-3 integrin was not found to be associated with lung cancer development. The role of ICAM-1 in the genesis of lung cancer as well as immune mechanism should be further investigated.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.